SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States for the Maintenance Treatment of COPD

January 22, 2015

RIDGEFIELD, CONN. -January 21, 2014- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is now available by prescription through retail pharmacies across the United States. 

Recently, SPIRIVA® RESPIMAT® was approved by the U.S. Food and Drug Administration (FDA), and was developed to deliver medication via a slow-moving mist that helps patients inhale the medication. 

“For 10 years, SPIRIVA HandiHaler has been a trusted maintenance therapy for patients with COPD, and Boehringer Ingelheim is proud to now offer another inhaler choice, SPIRIVA RESPIMAT,” said Danny McBryan, MD, vice president, Clinical Development & Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. “SPIRIVA RESPIMAT represents Boehringer Ingelheim’s continuing commitment to the COPD community to provide new treatment options.” 

Read the full release here. 

Join Us on COPD360social

Sign In to Participate
Or register to become a member